Skip to main content
. Author manuscript; available in PMC: 2024 Jan 30.
Published in final edited form as: J Infect Dis. 2009 Feb 1;199(3):381–390. doi: 10.1086/595830

Figure 3.

Figure 3.

Prevalence of neutralizing antibodies (NAbs) against different adeno-associated virus (AAV) types in 73 samples from Entebbe, Uganda; 60 from Kakira, Uganda; 60 from Kigali, Rwanda; 112 from Cape Town, South Africa; 51 from Nairobi, Kenya; and 51 from Lusaka, Zambia. Samples were considered positive if serum dilutions of >1:20 (A) or >1:80 (B) inhibited vector transduction by ≥50%. **Less prevalent than anti-AAV2 Nab (P < .05); ***less prevalent than anti-AAV2 and anti-AAV1 NAbs (P < .05); ****less prevalent than anti-AAV2, anti-AAV1, and anti-AAV7 Nabs (P < .05).